Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 7/16/19 (What's New)

Summary

  • Persistently detectable virus at insufficient levels for resistance testing (HIV-1 RNA 200-1000 copies/mL) is distinct from clinically irrelevant “blips”
  • Initial focus should be to assess adherence and potential for drug–drug or drug–food interactions
  • Considerable data support modifying the regimen of treatment–experienced patients to include 3 fully active agents or a fully active ritonavir-boosted PI with other fully or partially active drugs or dolutegravir in INSTI-naive patients plus 2 NRTIs where at least 1 is fully active[Aboud 2019]

Action required